Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.345 USD | +14.39% | +12.93% | -41.83% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-41.83% | 33.08M | C- | ||
+3.17% | 108B | B+ | ||
+10.37% | 105B | B+ | ||
+1.57% | 23.46B | B | ||
-13.18% | 21.72B | B+ | ||
-7.05% | 18.64B | A- | ||
-37.64% | 17.45B | A- | ||
-7.20% | 17.19B | B | ||
+5.84% | 13.99B | C+ | ||
+36.35% | 12.53B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PTN Stock
- Ratings Palatin Technologies, Inc.